



The Evolving Landscape of Bisphosphonate Therapy Novel Agents and Treatment Strategies

Jesper Webster*

School of Public Health and Preventive Medicine, Monash University, Bangladesh

Abstract

Bisphosphonates have long been essential in managing various bone-related disorders like osteoporosis and metastatic bone disease. However, recent advancements have led to the emergence of novel bisphosphonate agents and innovative treatment strategies, reshaping the therapeutic landscape. This article provides an overview of the latest developments in bisphosphonate therapy, highlighting novel agents, targeted delivery systems, combination therapies, and personalized approaches. By exploring these advancements, this article aims to offer insights into the evolving landscape of bisphosphonate therapy and its potential impact on bone health management.

***Corresponding author:** Jesper Webster, School of Public Health and Preventive Medicine, Monash University, Bangladesh, E mail: jesper.webster@gmail.com

Received: 01-March-2024, Manuscript No: joo-24-130335, **Editor Assigned:** 04-March-2024, pre QC No: joo-24-130335 (PQ), **Reviewed:** 18-March-2024, QC No: joo-24-130335, **Revised:** 22-March-2024, Manuscript No: joo-24-130335 (R), **Published:** 29-March-2024, DOI: 10.4172/2472-016X.1000255

Citation: Jesper W (2)

Discussion

10 .

Conclusion

Conflict of Interest

Acknowledgement

References

1. Meazza C, Scanagatta P (2016) Metastatic osteosarcoma: A challenging multidisciplinary treatment. *Exp Rev Anticancer Ther* 16: 543-556.
2. Geller DS, Gorlick R (2010) Osteosarcoma: A review of diagnosis, management, and treatment strategies. *Clin Adv Hematol Oncol HO* 8: 705-718.
3. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. *Drug Saf* 13: 228-244.
4. Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, et al. (2013) Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. *Pediatr Blood Cancer* 60: 580-586.
5. Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, et al. (2000) Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: Treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. *Oncol Rep* 7: 339-346.
6. McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS (2006) A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. *Pediatr Blood Cancer* 46: 345-350.
7. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, et al. (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. *Cancer Chemother Pharm* 31: 229-239.
8. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, et al. (2002) Phase II trial of gemcitabine in advanced sarcomas. *Cancer* 94: 3225-3229.
9. Ouyang Z, Li H, Zhai Z, Xu J, Dass CR, et al. (2018) Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma. *Curr Drug Targets* 19: 409-421.
10. Meyers PA (2004) High-dose therapy with autologous stem cell rescue for pediatric sarcomas. *Curr Opin Oncol* 16: 120-125.